Author

Takashi Ohmi

Institution: Pfizer (Japan)

Observed institution: Pfizer (Japan)

OpenAlex ID: A5113520460

Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model

2007 · Yoshinobu Ueno, Takashi Ohmi, et al. · Journal of Pharmacological Sciences · 23

Synthesis of benzamide derivatives as TRPV1 antagonists

2007 · Yuji Shishido, Madoka Jinno, et al. · Bioorganic & Medicinal Chemistry Letters · 18

Contribution of Active and Inactive States of the Human 5-HT4d Receptor to the Functional Activities of 5-HT4–Receptor Agonists

2008 · Tadayoshi Mikami, Hiromi Sugimoto, et al. · Journal of Pharmacological Sciences · 10

In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT4 receptor

2009 · Tadayoshi Mikami, Tohru Komada, et al. · European Journal of Pharmacology · 5

Synthesis and structure–activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease

2008 · Hirokazu Ueno, Makoto Kawai, et al. · Bioorganic & Medicinal Chemistry Letters · 3

Pharmacological characterization and determination of pharmacokinetic and pharmacodynamic relationship of PF-00885706, a novel partial agonist selective for the 5-HT4 receptor

2009 · Tohru Komada, Tomomi Matsuura, et al. · Pharmacological Research · 2

Works count: 6

Citation count: 61

H-index: 4

I10-index: 3